Abstract: A device for evaluating aspects of health of a residential property configured to: (i) receive a first element of internal home health data captured by one or more smart devices installed within a residential property, the first element of internal home health data reflecting an aspect of operational quality of one or more assets of the residential property; (ii) determine a safety score based upon the first element of internal home health data; (iii) receive a second element of internal home health data captured by the one or more smart devices; (iv) determine a home health score based upon the first or second elements of internal home health data, the home health score representing a measure of health of the residential property; and (v) cause to be displayed, to a homeowner via a graphical user interface, a home health evaluation that includes the safety score and the home health score.

Abstract: The disclosed invention relates to compositions and methods of administration to a subject, with bisbenzylisoquinolines such as 6,6?,7,12-tetramethoxy-2,2?-dimethyl-berbaman (tetrandrine, TET and ES-3000), and analogs, derivatives, isomers, and modified forms such as crystalline, salt forms, or a salt of this compound with a pharmaceutically acceptable acid or in combination with other agents which modulate ?-catenin and/or CaMKII? levels to either improve therapeutic outcome by enhancing expression of targets and/or decrease side effects of therapeutic regimens involving immunotherapies, such as checkpoint inhibitors and Chimeric antigen receptor T-cells (CAR-T).

Abstract: There is provided an aerosolizable gel comprising (a) an active agent; (b) one or more gel forming materials, wherein the one or more gel forming materials is at least agarose, wherein the agarose is present in an amount of 1 to 12 wt. % based on the aerosolizable gel; (c) an aerosol forming material; and (d) water.

Abstract: Disclosed are novel compositions, methods to improve a suboptimal therapeutic agent's performance in patients with cancer, infections, inflammatory, metabolic, immunological diseases. Describe are improvements ranging from pharmaceutical ingredients, dosage forms, excipients, solvents, diluents, drug delivery systems, preservatives, more accurate drug administrations, dose determination/schedules, toxicity monitoring and amelioration, techniques or agents. Using suboptimal therapeutic(s)s in conjunction with radiation(s) and/or conventional chemotherapeutic agent(s)s or biotherapeutic agent(s) including antibodies, vaccines, cytokines, lymphokines, gene and antisense RNA therapies, etc., would provide unique approaches, significant treatment improvement circumventing or reducing toxicity, including techniques and tools identifying/predicting patients by phenotype or genotype determination(s).

Abstract: The present disclosed invention provides pharmaceutical compositions and methods of use for bisbenzylisoquinolines such as 6,6?,7,12-tetramethoxy-2,2?-dimethyl-berbaman, and analogs, derivatives, isomers, and modified forms such as crystalline, salt forms, or a salt of this compound with a pharmaceutically acceptable acid or in combination with other agents to treat acute, chronic and pre-leukemic conditions as well as lymphomas and solid tumors. These include preneoplastic and neoplastic diseases and solid tumors including but not limited to acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), atypical chronic myeloid leukemia (aCML), and acute myeloid leukemia (AML), polycythemia vera (PV), chronic lymphoblastic leukemia (CLL), myeloproliferative syndrome (MPS), myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), myelofibrosis (MF), and polycythemia vera (PV).

Abstract: A crossflow filter device for filtering a pressurised feed liquid is provided. The crossflow filter device comprises: a filter membrane; a flow channel for the pressurised feed liquid which extends in a path over a retentate surface of the membrane such that the direction of flow in the channel is tangential to the retentate surface, and a filtrate derived from the feed liquid passes through the membrane leaving retentate liquid in the flow channel; and a collection chamber for the filtrate formed on an opposite, filtrate surface of the membrane. The crossflow filter device further comprises a sealed housing having a retentate side and a filtrate side which enclose therebetween the flow channel, the filter membrane and the collection chamber. The crossflow filter device further comprises, flow channel guide walls provided at an inner surface of the retentate side of the housing.

Abstract: A bioreactor for use on a moving platform including a bag. According to a first aspect, the bag defines a three-dimensional geometrical shape including at least one lower collecting vertex in which at least two edges of the geometrical shape meet at an angle not greater than 90°. The bioreactor further includes at least one port or sensor arranged in the vicinity of the collecting vertex. According to a second aspect, the bag defines a two-dimensional geometrical shape or a three-dimensional geometrical shape. The geometrical shape includes at least one edge, in which at least two faces of the geometrical shape meet at an angle not greater than 90°. A longitudinal port/sensor element is arranged along the edge and includes several ports and/or sensors. A bioreactor motion system including a moving platform and a bioreactor according to the first or second aspect. A method of performing a bioprocess.

Abstract: The present disclosure relates to systems and methods for optimizing refueling hydrogen in vehicles. Specifically, the present disclosure relates to identifying a refueling station, conducting a safety check on the vehicle based on a distance between the vehicle and the refueling station, switching a power source of the vehicle to only be a battery, swapping an empty or partially filled hydrogen fuel tank on the vehicle with a filled or partially filled hydrogen fuel tank at the refueling station, and switching the power source of the vehicle to include a hydrogen power source.

Abstract: There is provided an aerosolizable gel comprising (a) an active agent; (b) one or more gel forming materials, wherein the one or more gel forming material is at least one phyllosilicate; (c) an aerosol forming material selected from glycerol, propylene glycol and mixtures thereof; and (d) water.

Abstract: The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.

Abstract: The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.

Abstract: The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.

Abstract: Implementations described herein relate to features for an integrated aftertreatment system. In one implementation, an integrated aftertreatment system comprises a casing that includes a mating flange having a first constant diameter and a catalyst component configured to mate to the mating flange of the casing. The catalyst component includes a canned body including a first portion sized to a second constant diameter to mate with the first constant diameter of the mating flange. In another implementation, an integrated aftertreatment system comprises a casing, a catalyst component positioned within the casing, a particulate filter having an outer casing with an outlet, and a particulate filter joint coupled to the outer casing of the particulate filter at the outlet. An end of the particulate filter joint is aligned with an end of the particulate filter.

Abstract: A crossflow filter device for filtering a pressurised feed liquid is provided. The crossflow filter device comprises: a filter membrane; a flow channel for the pressurised feed liquid which extends in a path over a retentate surface of the membrane such that the direction of flow in the channel is tangential to the retentate surface, and a filtrate derived from the feed liquid passes through the membrane leaving retentate liquid in the flow channel; and a collection chamber for the filtrate formed on an opposite, filtrate surface of the membrane. The crossflow filter device further comprises a sealed housing having a retentate side and a filtrate side which enclose therebetween the flow channel, the filter membrane and the collection chamber. The crossflow filter device further comprises, flow channel guide walls provided at an inner surface of the retentate side of the housing.

Abstract: There is provided an aerosolizable gel comprising (a) an active agent; (b) one or more gel forming materials, wherein the one or more gel forming materials is at least agarose, wherein the agarose is present in an amount of 1 to 12 wt. % based on the aerosolizable gel; (c) an aerosol forming material; and (d) water.

Abstract: There is provided an aerosolizable gel comprising (a) an active agent; (b) one or more gel forming materials, wherein the one or more gel forming material is at least one phyllosilicate; (c) an aerosol forming material selected from glycerol, propylene glycol and mixtures thereof; and (d) water.

Abstract: Implementations described herein relate to features for an integrated aftertreatment system. In one implementation, an integrated aftertreatment system comprises a casing that includes a mating flange having a first constant diameter and a catalyst component configured to mate to the mating flange of the casing. The catalyst component includes a canned body including a first portion sized to a second constant diameter to mate with the first constant diameter of the mating flange. In another implementation, an integrated aftertreatment system comprises a casing, a catalyst component positioned within the casing, a particulate filter having an outer casing with an outlet, and a particulate filter joint coupled to the outer casing of the particulate filter at the outlet. An end of the particulate filter joint is aligned with an end of the particulate filter.

Abstract: Disclosed is a connection system for releasably coupling a first body (5) with a flange (25) to a fluid-conducting system in a force-fitting manner, and the invention also relates to a connection system for releasably coupling the interior of a first fluid-conducting body (5) to the interior of a second fluid-conducting body (3) in a force-fitting manner. The second body (3) has a second end with a circumferential wall (22), a membrane contact portion (9) which can be found on the wall, and an opening (43). A retaining element (2) has a passage (35) and a peripheral outer edge (24). One side and/or the passage (35) of the retaining element (2) is coupled to the membrane (1), and an annular wall (26) is arranged on the same side, said annular wall being connected to the circumferential wall (22) of the second body (3). The other side is designed to contact the surface of the flange (25) of the first body (5).

Abstract: Implementations described herein relate to features for an integrated aftertreatment system. In one implementation, an integrated aftertreatment system comprises a casing that includes a mating flange having a first constant diameter and a catalyst component configured to mate to the mating flange of the casing. The catalyst component includes a canned body including a first portion sized to a second constant diameter to mate with the first constant diameter of the mating flange. In another implementation, an integrated aftertreatment system comprises a casing, a catalyst component positioned within the casing, a particulate filter having an outer casing with an outlet, and a particulate filter joint coupled to the outer casing of the particulate filter at the outlet. An end of the particulate filter joint is aligned with an end of the particulate filter.